Showing posts with label patents. Show all posts
Showing posts with label patents. Show all posts
Sunday, May 31, 2015
F.T.C. Settlement Indicates Determination To Increasing Competition In The Pharmaceutical Industry
Teva Settles Cephalon Generics Case With F. T.C. For $1.2 Billion by Rebecca R. Ruiz And Katie Thomas. May 28, 2015.
Tuesday, April 16, 2013
Patenting Human Genes At Issue In Supreme Court Hearing
Argument Recap: Analogies To The Rescue by Lyle Denniston. Scotusblog.com. April 15, 2013.
The Supreme Court appeared skeptical that Myriad Genetics was legally entitled to patent a fragment of naturally-occuring DNA that could be used to suggest a risk in women for breast or ovarian cancer. Most of the justices, "imperfectly versed in biochemistry," sought out analogical language to express the concepts of the case.
The Supreme Court appeared skeptical that Myriad Genetics was legally entitled to patent a fragment of naturally-occuring DNA that could be used to suggest a risk in women for breast or ovarian cancer. Most of the justices, "imperfectly versed in biochemistry," sought out analogical language to express the concepts of the case.
Tuesday, April 2, 2013
Access To Drugs and Intellectual Property Rights Clash In Case With Worldwide Implications
Novartis Cancer-Drug Patent Denied By India Supreme Court. by Eva Von Schaper and Pratap Patnaik. Bloomberg. April 1, 2013.
Low-Cost Drugs In Poor Nations Get A Lift In Indian Court by Gardiner Harris and Katie Thomas. The New York Times. April 1, 2013.
Drug pricing is a source of dispute between the developed and developing world. The price differences between patented drugs produced by large pharmaceutical companies and generic versions produced in developing countries can be tremendous. As a result the ruling of the Indian Supreme Court that Novartis' leukemia drug Gleevec was not subject to patent protection under Indian law.
The two articles provide a political, medical, innovative, corporate, economic, competitive, human rights, and global context to the ruling.
Low-Cost Drugs In Poor Nations Get A Lift In Indian Court by Gardiner Harris and Katie Thomas. The New York Times. April 1, 2013.
Drug pricing is a source of dispute between the developed and developing world. The price differences between patented drugs produced by large pharmaceutical companies and generic versions produced in developing countries can be tremendous. As a result the ruling of the Indian Supreme Court that Novartis' leukemia drug Gleevec was not subject to patent protection under Indian law.
The two articles provide a political, medical, innovative, corporate, economic, competitive, human rights, and global context to the ruling.
Sunday, March 3, 2013
Genetics Cases Before The Supreme Court
What is A Gene and How Does It Apply To The Law? The Supreme Court Still Doesn't Know by Brian Resnick. National Journal. March 1, 2013.
The article briefly summarizes three cases coming before the Supreme Court this session. The one most relevant for human health is Association for Molecular Pathology v. Myriad Genetics. Myriad claims that their efforts to isolate the BRCA gene from a strand of DNA was patentable. The Association claims that giving monopoly protection to Myriad is unfair and inhibits cancer research.
The article briefly summarizes three cases coming before the Supreme Court this session. The one most relevant for human health is Association for Molecular Pathology v. Myriad Genetics. Myriad claims that their efforts to isolate the BRCA gene from a strand of DNA was patentable. The Association claims that giving monopoly protection to Myriad is unfair and inhibits cancer research.
Wednesday, February 27, 2013
Biotech Drugs Still Won't Copy by Christopher Weaver, Jeanne Whalen and Jonathan D. Rockoff. The Wall Street Journal. February 26, 2013.
Conventional drugs can be duplicated by reproducing the formula. Biotech drugs are products of living cells with altered DNA and are more difficult to reproduce. The difference between conventional and biotech has significance when patent protection of a drug expires and when generics move into the gap. While generics of conventional drugs are identical to the original, the similarity of the generics of biotech drugs is more difficult to assess. The article present issues involved in biosimilar drugs, or the generic equivalent of the biotech drugs.
Conventional drugs can be duplicated by reproducing the formula. Biotech drugs are products of living cells with altered DNA and are more difficult to reproduce. The difference between conventional and biotech has significance when patent protection of a drug expires and when generics move into the gap. While generics of conventional drugs are identical to the original, the similarity of the generics of biotech drugs is more difficult to assess. The article present issues involved in biosimilar drugs, or the generic equivalent of the biotech drugs.
Subscribe to:
Posts (Atom)